These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8078420)

  • 1. The importance of oxygen in the killing of bacteria by ofloxacin and ciprofloxacin.
    Morrissey I; Smith JT
    Microbios; 1994; 79(318):43-53. PubMed ID: 8078420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vivo bactericidal effect of ciprofloxacin, ofloxacin and pefloxacin against Staphylococcus aureus].
    Tronel H; Voiriot P; Weber M; Dopff C; Dewachter P; Phelisse F; Dureux JB
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):578-81. PubMed ID: 2797882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis.
    Parte AC; Smith JT
    Microbios; 1994; 79(319):87-95. PubMed ID: 7968664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of quinolones against slowly growing bacteria.
    Dalhoff A; Matutat S; Ullmann U
    Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
    Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
    J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin.
    Lewin CS; Amyes SG
    J Med Microbiol; 1989 Nov; 30(3):227-31. PubMed ID: 2479750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
    Kowalski RP; Karenchak LM; Gordon YJ
    Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial effects of chitosans and chitooligosaccharides, upon Staphylococcus aureus and Escherichia coli, in food model systems.
    Fernandes JC; Tavaria FK; Soares JC; Ramos OS; João Monteiro M; Pintado ME; Xavier Malcata F
    Food Microbiol; 2008 Oct; 25(7):922-8. PubMed ID: 18721683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal mechanisms of ofloxacin.
    Lewin CS; Smith JT
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():1-8. PubMed ID: 3053574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
    Howard BM; Pinney RJ; Smith JT
    Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light effect and reactive oxygen species in the action of ciprofloxacin on Staphylococcus aureus.
    Becerra MC; Sarmiento M; Páez PL; Argüello G; Albesa I
    J Photochem Photobiol B; 2004 Oct; 76(1-3):13-8. PubMed ID: 15488711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
    Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
    Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.